The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new antibody treatment ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

RSV is the focus of a new national pediatric guideline in China aimed at standardizing diagnosis, treatment, and prevention strategies for respiratory tract infections in children ...